Raised$11.8M
Founded2021
Employees2
LocationDurham, NC
About
Clinical stage drug development company
Product
- Value proposition
- Developing novel therapeutics for metabolic and gastrointestinal diseases, including post bariatric hypoglycemia and gastroparesis.
Founders
- James Green
Products
mizagliflozin (lead compound)
Key features
oral small-molecule inhibitor of SGLT1reduces postprandial glucose absorptionreduces insulin and GIP secretion
Technologies
SGLT1 inhibitorsmall molecule drug candidate
Target conditions
post bariatric hypoglycemiagastroparesisobesity
Investors
Kissei Pharmaceuticals, Ltd.
News
- Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference · 2025-04-15T14:45:00.000Z
- Vogenx has filed a notice of an exempt offering of securities to raise $5 Million in New Funding. - intelligence360 · 2026-02-02T19:23:27.000Z
- S-1 - SEC.gov · 2024-08-23T00:00:00.000Z
- Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference · 2025-04-15T18:45:00.000Z
- 10-K - SEC.gov · 2025-03-17T00:00:00.000Z
- Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference · 2025-04-15T18:57:39.000Z
More links
Browse similar startups
Related startups
- Waypoint Counseling & Maternal Wellness, PLLC — Durham, NC
- 9+1AI — Charlotte, NC
- Blueprint Nutrition & Fitness — Charlotte, NC
- Carolina Behavioral Health — Burlington, NC
- CollectiveGood Health — Chapel Hill, NC
- DiabesityMD — Raleigh, NC
- Voxology AI — Austin, TX
- VRA Vision — Sioux Falls, SD
- WAUKESHA PEDIATRIC ASSOCIATES, LTD. — Waukesha, WI
- Way — Santa Monica, CA
- We Rise Veterans — Denver, CO
- Weight Sense — Orlando, FL
Profile updated Jul 29, 2026. Sources: vogenx.com
